Loading your page…
Frontiers in immunology
By Huang J, Li Y, Peng Y and 3 others.
Paediatric generalised pustular psoriasis (GPP) is rare, frequently relapsing and associated with limited evidence for targeted therapy. Vunakizumab is an anti-interleukin-17A monoclonal antibody, but data in paediatric GPP are scarce.
Ward brings these articles into the same app as your cards and questions. One free account for Ward, Suture, Osler and Prognia.
We retrospectively reviewed three boys with recurrent GPP who received short-course vunakizumab during acute flares. Clinical characteristics, diagnostic details, treatment timelines, follow-up outcomes and Generalized Pustular Psoriasis Area and Severity Index (GPPASI) scores were collected.
A 13-year-old boy (87.5 kg) with ciclosporin-dependent recurrent GPP received vunakizumab 240 mg at weeks 0 and 2 with concomitant topical therapy; GPPASI decreased from 18 to 1, and no relapse was documented during approximately 6 months of follow-up. An 8-year-old boy (35 kg) received a single 120-mg administration; GPPASI decreased from 11 to 2, and no recurrent pustular eruption was reported during approximately 15 months of available follow-up, which was predominantly remote after the initial visit. Another 8-year-old boy (32 kg) with a febrile flare received two 120-mg administrations; GPPASI decreased from 14 to 2, and no relapse was documented during approximately 3 months of follow-up. No adverse events considered treatment-related were documented during the available observation periods.
Short-course vunakizumab was temporally associated with rapid clinical improvement in three paediatric patients with acute GPP flares. Larger prospective studies with standardised follow-up are needed to evaluate efficacy, paediatric dosing, relapse prevention and long-term safety.
Published in Frontiers in immunology. The abstract is shown as published and remains the work of its authors; read the full article at the source.
Prognia lists this article for reference and education. It is not medical advice. Always read the original and follow current guidelines and local protocols before acting on it.
